Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 1Bronchiolitis Obliterans Syndrome 1Agnosia 1

Interventions

Oxycodone 1Naloxone 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Bronchiolitis Obliterans Syndrome × Oxycodone × Clear all
NCT02321397 2016-11-04

To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain

Mundipharma Research GmbH & Co KG

Phase 2/3 Completed
155 enrolled

Bronchiolitis Obliterans Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡